Publications

Publications Content

Research Publication (last 3 years)

  • Yun, E.J., Zhou, J., Lin, C-H., Hernandez, E., Fazli, L., Gleave,, Hsieh, J.T. (2016) Targeting cancer stem cell in castration resistant prostate cancer. Clin. Cancer Res., 22:670-679. PMID26876207
  • Zhou, J.C., Zhu, G., Huang, J., Li, L., Du, Y., Gao, Y., Wu, D., Wang, X., Hsieh, J.T., He, D., Wu K. (2016) Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target. Cancer Lett. 370:313-23.
  • Yu, M., Zhou, J., Du, B., Ning, X., Authement, C., Gandee, L., Kapur, P., Hsieh, J.T., Zheng, J. (2016) Noninvasive staging of kidney dysfunction enabled by renal clearable luminescent gold nanoparticles nanofluorophores. Angewandte Chemie, 55: 2787-2791. PMID26800513 PMCID4834218
  • Kumar, A., Mastren, T.,Wang, B., Hsieh, J.T., Hao, G., Sun, X. (2016) Design of Small-molecule Drug Conjugates for Prostate Cancer Targeted Theranostics. Bioconjug. Chem., 27:1681-1699. PMID27248781
  • Zhou, J., Wu, K., Luo, J., Yun, E.J., Kapur, P., Pong, R.C., Du, Y., Wang, B., Authement, C., Hernandez, E., Jichen Yang, J., Xiao, G., Cha, T-L., Wu, H-C., Wu, D., Margulis, V., Lotan, Y., Brugarolas, J., He, D., Hsieh, T. (2016) Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene, 35:4663-4674. PMID26876207
  • Wang, Z-R., Wei,H., Zhou , J.C., Haddad, A., Zhao, L.Y., Kapur, P., Wu, K., Wang, B., Yu, Y-H., Liao, B., He, D., Chen, W., Margulis, V., Hsieh, J.T., Luo, J-H.. (2016) Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget, 7:31508-31519. PMID27129174.
  • Huang, J., Wang, B., Hui, K., Zeng, J., Fan, J., Wang, X., Hsieh, J.T., He, D., Wu, K. (2016) miR-92b targets DAB2IP to promote EMT in bladder cancer migration and invasion. Rep., 36:1693-1701. PMID27430302
  • Wang, B., Huang, J., Zhou, J., Hui, K., Xu, S., Fan, J., Li, L., Wang, X., Hsieh, J.T., He, D., Wu, K. (2016) DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein. Cell. Signaling, 28:1623-1630. PMID27476001
  • Yu, L., Shang, Z.F., Abdisalaam, S., Lee, K.J., Gupta, A., Hsieh, J.T., Aroumougame, A., Chen, B., Saha, D. (2016) Tumor Suppressor Protein DAB2IP Participates in Chromosomal Stability Maintenance through Activating Spindle Assembly Checkpoint and Stabilizing Kinetorchore-Microtubule Attachments. Nucleic Acids Res., 44:8842-8854. PMID27568005
  • Huang, P-H., Chen, M-C., Lai, C.H. Hsieh, J.T., Wang, J-H., Peng, Y-T., Lee, Y., Lin , E., Yue, C-H., Wang, H-Y., You, S-C., Lin, H. (2016) Cdk5 directly targets nuclear p21CIP1 and promotes cancer cell growth. Cancer Res., 76:6888-6900. PMID27909065
  • Huang, W.Y., Lin, J.N., Hsieh, J.T., Chou, S.C., Lai, C.H., Yun, E.J., Lo, U., Pong, R.C., Lin, J.H., Lin, Y.H. (2016) Nanoparticle targeting CD44-positive cancer cells for Site-specific drug delivery in prostate cancer therapy. ACS Appl. Mater. Interfaces, 8:30722-30734. PMID27786455
  • Chen, W., Zhou, J., Wu, K., Huang, J., Ding, Y., Yun, E-J., Wang, B., Ding, , Hernandez, E., Santoyo, J., Chen, H., Lin, H., Sagalowsky, A., He, D., Zhou, J., Hsieh, J.T. (2016) Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. Oncotarget, 7:56842-56854. PMID27472396
  • Chen, Y.A., Lien, H.M., Kao, M.C., Lo, U., Lin, L.C., Lin, C. J., Chang, S.J., Chen, C.C., Tang, C.H., Lin, H., Hsieh, J.T., Lai C.H. (2016) Sensitization of radioresistant prostate cancer cells by resveratrol isolated from Arachis hypogaea stems. PLoS One, 12:e0169204. PMID28081154
  • Lai, C.K., Chen, A., J.C., Lin, C.J., Kao, M.C., Huang, M.Z., Lin, Y.H., Chuan C.N., Lo, U., Lin, L.C., Lin, H., Hsieh, J.T., Lai, C.H. (2016) Molecular mechanisms of interactions between membrane cholesterol and cytolethal distending toxin in Campylobacter jejuni. Front. Cell. Infect. Microbiol., 6:1-8.
  • Liu, L., Xu, C., Hsieh, J.T., Gong, J., Xie, D. (2016) DAB2IP in cancer. Oncotarget 7:3766-3776. PMID26658103
  • Yun, E., Lo, U., Hsieh, J.T. (2016) The evolving landscape of prostate cancer stem cell (PCSC): therapeutic implications and future challenges. Asian J. Urol., 3:203-210. PMID29264188
  • Lin, L-C., Gao, A.C., Lai, C.H., Hsieh, J.T., Lin, H. (2017) Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) through exosomes released from adjacent cancer cells. Cancer Letters, 391:74-82. PMID28109910
  • Hui, K., Gao, Y., Huang, J., Xu, S., Wang, B., Zeng, J., Fan, J., Wang, X., Yue, Y., Wu, S., Hsieh, J.T., He, D., Wu, K. (2017) RASAL2, a RAS GTPase activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Cell Death Dis., 8:e2600. PMID28182001
  • Zhou, J., Yun, E.J., Chen, W., Ding, Y., Wu, K., Wang, B., Ding, C., Elizabeth Hernandez, E., Santoyo, J., Pong, R.C., Chen, H., He, D., Zhou, J., Hsieh, J.T. (2017) Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogues. Cell Death Dis., 8:e2701. PMID28333136
  • Yun, E.J., Zhou, J., Lin, C-J., Hernandez, E., Santoyo, , Hernandez, E., Lai, C-H., Lin, H., He, D., Hsieh, J.T. (2017) The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes. Oncotarget, 8:66975-66986. PMID28537931
  • Miao, L., Yang, L., Li, R., Nava Rodrigues D., Crespo, M., Hsieh, J.T., Tilley, W.D., de Bono, J.S., Selth, L.A., Raj, G.V. (2017) Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Res., 77:3101-3112. PMID28302679
  • Wang, B., Lo, U., Wu, , Kapur, P., Liu, X., Huang, J., Chen, W., Hernandez, E., John Santoyo, J., Ma, S-H., Pong, R-C., He, D., Cheng, Y-Q., Hsieh, J.T. (2017) Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. International J Cancer, 141: 2121-2130. PMID28722220
  • Xie, Z., Su, Y., Selvi, E., Kim, G.B., Ma, C., Aragon-Sanabna, V., Dong, C., Hsieh, J.T., Yang J. (2017) Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery. Small, 13:1603121-1603130. PMID28026115
  • Xu, , Yu, M., Carter, P., Hernandez, E., Dang, A., Kapur, P., Hsieh, J.T., Zheng, J. (2017) In Vivo X-ray Imaging of Transport of Renal Clearable Gold Nanoparticles in the Kidneys. Angewandte Chemie, 56:13356-13360. PMID28881491
  • Lo, U., Lee, C.F., Lee, M.S., Hsieh, J.T. (2017) The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. Int. J. Mol. Sci., 18: pii: E2079. PMID28973968
  • Shan, D., Hsieh, J.T., Bai, X., Yang, J. (2018) Citrate-based fluorescent biomaterials. Adv Healthc Mater. e1800532. PMID30047618
  • Tai, Y.L, Chen, K.C., Hsieh, J.T., Shen, T.L. (2018) Exosomes in cancer development and clinical applications. Cancer Sci., 109:2364-2374. PMID29908100
  • Xu, J., Yu, M., Peng, C., Carter, P., Tian, J., Ning, X., Zhou, Q., Tu, Q., Zhang, G., Dao, A., Jiang, X., Kapur, P., Hsieh, J.T., Zhao, X., Liu, P., Zheng, J. (2018) Dose Dependencies and Biocompatibility of Renal Clearable Gold Nanoparticles: From Mice to Non-human Primates. Angewandte Chemie, 56:266-271. PMID29160029
  • Chen, Y.A., Shih, H.W., Lin, Y.C., Hsu, H-Y., Wu, T.F., Tsai, C.H., Wu, H.Y., Hsieh, J.T., Tang, C.H., Lai, C.H. (2018) Simvastatin sensitizes radioresistant prostate cancer cells to radiation. Front Pharmacol., 9:600. doi: 10.3389. PMID29950990
  • Cai, H., Xie, F., Mulgaonkar, A., Chen, L., Sun, X., Hsieh, J.T., Peng, F., Tian, R., Li, L., Wu, C., Ai, H. (2018) Bombesin functionalized 64Cu-copper sulfide nanoparticles for targeted imaging of orthotopic prostate cancer. Nanomedicine, doi: 10.2217. PMID29786467
  • Hui, K, Wu, S, Yue, Y, Gu, Y, Guan, B, Wang, X, Hsieh, JT, Chang, LS, He, D, Wu, K. (2018) RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer. Cell Signal., 48:38-44. PMID9702203
  • Zhu J, Huang Z, Zhang M, Wang W, Liang H, Zeng J, Wu K, Wang X, Hsieh JT, Guo P, Fan J. (2018) HIF-1α promotes ZEB1 expression and EMT in a human bladder cancer lung metastasis animal model. Oncol Lett., 15:3482-3489. PMID29467870
  • Hui, K., Yue, Y, Wu, S,, Gu, Y, Guan, B, Wang, X, Hsieh, JT, Chang, LS, He, D, Wu, K. (2018) The expression and function of RASAL2 in renal cell carcinoma angiogenesis. Cell Death Dis., 9:881. PMID30158581
  • Wang, B., Gu, Y., Hui, K., Huang, J., Xu, S., Wu, S, Li, L., Fan, J., Wang, X., Hsieh, J.T., He, D., Wu, , (2018) AKR1C3, a crucial steroidogenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. Urol Oncol., 36:472.e11-20. PMID30139661
  • Chen, Y-A., Tzeng, T.W., Huang, Y-P., Lin, C-J., Lo, U., Wu, C-L., Lin, H., Hsieh, J.T., Tang, C-H., Lai, C.H. (2019) Antrocin sensitizes prostate cancer cells to radiotherapy throughinhibiting PI3K/AKT and MAPK signaling pathways. Cancers, 11: E34. PMID30602706
  • Lo, U., Pong, R.C., Yang, D., Gandee, L., Hernandez, E., Dang, A., Lin, C-J., Santoyo, J., Ma, S-H., Sonavane, R., Huang, J., Tseng, S-F., Moro, L., Arbini, A.A, Kapur, P., Raj, G., He, D., Lai, C.H., Lin, H., Hsieh, J.T. (2019) IFN-g-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via microRNAs processing. Cancer Res., 79:1098-1112. PMID0504123